BioStem Technologies, Inc. (NASDAQ:BSEM)
| Market Cap | 73.20M-21.8% |
| Revenue (ttm) | -60.31M-119.6% |
| Net Income | -28.29M-207.7% |
| EPS | -1.68-251.5% |
| Shares Out | 16.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 142,917 |
| Open | 4.23 |
| Previous Close | 4.17 |
| Day's Range | 4.17 - 4.45 |
| 52-Week Range | 2.25 - 8.40 |
| Beta | 0.26 |
| Analysts | n/a |
| Price Target | 7.00(+62.41%) |
| Earnings Date | Nov 12, 2026 |
About BSEM
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
$BSEM stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in BSEM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BSEM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BSEM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New BSEM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BSEM from public contracts
Source: USAspending.gov
BSEM Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BSEM’s recent data — informational, not investment advice